Categories: Metabolic diseases, Rare diseases

Aliases & Classifications for Hemosiderosis

MalaCards integrated aliases for Hemosiderosis:

Name: Hemosiderosis 12 73 20 54 44 15 70
Haemosiderosis 12
Iron Overload 70


External Ids:

Disease Ontology 12 DOID:12119
MeSH 44 D006486
NCIt 50 C82892
SNOMED-CT 67 39011001
UMLS 70 C0019114 C0282193

Summaries for Hemosiderosis

Disease Ontology : 12 An iron metabolism disease that has material basis in an accumulation of hemosiderin, an iron-storage complex, resulting in iron overload.

MalaCards based summary : Hemosiderosis, also known as haemosiderosis, is related to pulmonary hemosiderosis and aceruloplasminemia. An important gene associated with Hemosiderosis is CP (Ceruloplasmin), and among its related pathways/superpathways are Insulin receptor recycling and Metal ion SLC transporters. The drugs Deferoxamine and Deferiprone have been mentioned in the context of this disorder. Affiliated tissues include liver, bone marrow and kidney, and related phenotypes are cellular and hematopoietic system

Wikipedia : 73 Hemosiderosis is a form of iron overload disorder resulting in the accumulation of... more...

Related Diseases for Hemosiderosis

Diseases related to Hemosiderosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 451)
# Related Disease Score Top Affiliating Genes
1 pulmonary hemosiderosis 32.8 PRTN3 MIF KRT7
2 aceruloplasminemia 30.9 TFR2 SLC40A1 SLC11A2 HJV HFE HAMP
3 atransferrinemia 30.5 TFR2 TF SLC40A1 SLC11A2 HJV HFE
4 sickle cell disease 30.2 TF HP EPO
5 hemolytic anemia 30.1 TF HP HFE EPO
6 hemoglobin h disease 30.1 TF HAMP EPO
7 respiratory failure 30.0 TF GPT EPO ALB
8 celiac disease 1 30.0 HP HFE GPT ALB
9 rare hereditary hemochromatosis 29.9 TFR2 TF SLC40A1 HJV HFE HAMP
10 siderosis 29.8 TF SLC40A1 HFE HAMP GPT CP
11 congenital dyserythropoietic anemia 29.8 HFE HAMP EPO
12 hypochromic microcytic anemia 29.8 TF SLC11A2 HJV HAMP CP
13 viral hepatitis 29.6 HFE GPT CP ALB
14 exanthem 29.6 PRTN3 GPT ALB
15 wilson disease 29.5 HP HFE GPT CP
16 liver cirrhosis 29.5 TF HP HFE GPT CP ALB
17 iga glomerulonephritis 29.5 PRTN3 MIF ALB
18 beta-thalassemia 29.5 TFR2 TF HJV HFE HAMP GPT
19 neutropenia 29.4 GPT EPO CP ALB
20 hypersplenism 29.4 GPT EPO ALB
21 alcoholic liver cirrhosis 29.4 TF GPT ALB
22 pancytopenia 29.4 U2AF1 HP EPO CP
23 sideroblastic anemia 29.3 TFR2 SLC40A1 HAMP
24 iron metabolism disease 29.3 TFR2 TF SLC40A1 SLC11A2 HJV HFE
25 miliary tuberculosis 29.3 EPO ALB
26 iron deficiency anemia 29.3 TFR2 TF SLC40A1 SLC11A2 HJV HFE
27 cholelithiasis 29.2 HP GPT ALB
28 alcohol use disorder 29.2 TF HFE GPT ALB
29 alpha-thalassemia 29.1 HP HFE HAMP EPPIN EPO
30 esophageal varix 29.1 HP GPT CP ALB
31 cerebellar disease 29.1 U2AF1 EPPIN CP
32 liver disease 29.0 TF SLC40A1 HFE GPT CP ALB
33 myelodysplastic syndrome 29.0 U2AF1 HFE HAMP EPO ALB
34 primary biliary cholangitis 28.9 PRTN3 KRT7 GPT CP ALB
35 chronic kidney disease 28.9 TF HP HAMP EPO ALB
36 anemia, sideroblastic, 1 28.9 TFR2 SLC40A1 SLC11A2 HJV HAMP
37 kidney disease 28.8 TF PRTN3 HP EPO ALB
38 acute kidney failure 28.8 PRTN3 HP GPT ALB
39 microcytic anemia 28.6 TFR2 TF SLC40A1 SLC11A2 HJV HAMP
40 cystic fibrosis 28.6 PRTN3 HP HFE CP ALB
41 hemoglobinopathy 28.2 TFR2 TF HP HJV HFE HAMP
42 diabetes mellitus 28.2 TF MIF HP HFE GPT EPO
43 hemochromatosis, type 1 28.1 TFR2 TF SLC40A1 SLC11A2 HP HJV
44 porphyria 28.1 TFR2 SLC40A1 HJV HFE HAMP EPO
45 porphyria cutanea tarda 27.9 TFR2 TF SLC40A1 HJV HFE HAMP
46 deficiency anemia 27.2 U2AF1 TFR2 TF SLC40A1 SLC11A2 PRTN3
47 superficial siderosis 11.4
48 gracile syndrome 11.2
49 heiner syndrome 11.0
50 secondary pulmonary hemosiderosis 11.0

Graphical network of the top 20 diseases related to Hemosiderosis:

Diseases related to Hemosiderosis

Symptoms & Phenotypes for Hemosiderosis

MGI Mouse Phenotypes related to Hemosiderosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 ALB CAT CP EPO HFE HP
2 hematopoietic system MP:0005397 10 CP EPO HFE HJV HP MIF
3 homeostasis/metabolism MP:0005376 9.97 ALB CAT CP EPO HFE HJV
4 immune system MP:0005387 9.73 ALB CP EPO HFE HJV HP
5 liver/biliary system MP:0005370 9.28 ALB CP EPO HFE HJV HP

Drugs & Therapeutics for Hemosiderosis

Drugs for Hemosiderosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
Deferiprone Approved Phase 4 30652-11-0 2972
Iron Approved Phase 4 7439-89-6 23925 29936
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381 214348
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
Trichostatin A Experimental Phase 4 58880-19-6
7 Pharmaceutical Solutions Phase 4
8 Antioxidants Phase 4
9 Trace Elements Phase 4
10 Nutrients Phase 4
11 Vitamins Phase 4
12 Micronutrients Phase 4
13 Protective Agents Phase 4
14 Chelating Agents Phase 4
15 Iron Chelating Agents Phase 4
16 Immunosuppressive Agents Phase 4
17 Cyclosporins Phase 4
Zinc Approved, Investigational Phase 3 7440-66-6 32051
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2, 11096-26-7
22 Orange Approved Phase 3
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
tannic acid Approved Phase 3 1401-55-4
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
26 Zinc Supplement Phase 3
27 silymarin Phase 2, Phase 3
28 Omega 3 Fatty Acid Phase 2, Phase 3
29 Nigella Phase 2, Phase 3
30 Calcium, Dietary Phase 2, Phase 3
31 Ferric Oxide, Saccharated Phase 2, Phase 3
32 Epoetin alfa Phase 2, Phase 3 113427-24-0
33 Vasodilator Agents Phase 2, Phase 3
34 Antihypertensive Agents Phase 2, Phase 3
35 calcium channel blockers Phase 2, Phase 3
36 Hormones Phase 2, Phase 3
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
39 Hepcidins Phase 2
40 Vitamin B 6 Phase 2
41 Anti-Infective Agents Phase 2
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
Nifedipine Approved Phase 1 21829-25-4 4485
Acetylcysteine Approved, Investigational Phase 1 616-91-1 12035
Cysteine Approved, Nutraceutical Phase 1 52-90-4 5862
46 Tocolytic Agents Phase 1
47 Respiratory System Agents Phase 1
48 Antidotes Phase 1
49 Expectorants Phase 1
50 N-monoacetylcystine Phase 1

Interventional clinical trials:

(show top 50) (show all 175)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Unknown status NCT02041299 Phase 4 Deferiprone;Deferoxamine
2 A Single-arm, Open-label Study of the Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food Completed NCT00845871 Phase 4 deferasirox:
3 1-year Extension to CICL670A2402 an Open-label, Multi-center Trial of the Efficacy and Safety of Long-term Treatment With Deferasirox (10 to 20 mg/kg/Day) in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2- Year Duration) Completed NCT00171301 Phase 4 Deferasirox
4 Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia Completed NCT03591575 Phase 4 Deferiprone oral solution;Placebo
5 A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 in Patients Diagnosed With Low and INT-1 Risk Myelodysplastic Syndrome (MDS) and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4 ICL670/Deferasirox
6 A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present Completed NCT00654589 Phase 4 Deferasirox
7 A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Completed NCT03372083 Phase 4 Deferasirox
8 Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4 deferasirox
9 Increased Survival and Reversion of Iron-Induced Cardiac Disease in Patients With Thalassemia Major Receiving Intensive Combined Chelation Therapy Completed NCT00800761 Phase 4 Deferoxamine and Deferiprone;Deferoxamine
10 A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation. Completed NCT01610297 Phase 4 ICL670
11 A Single Arm, Multicenter, Open Label Study of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Completed NCT01546415 Phase 4 Desferasirox
12 Safety of Deferasirox (ICL670) and Deferoxamine (Desferal or DFO) Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload Completed NCT00901199 Phase 4 Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)
13 A Phase IV , Multicenter ,Open Label ,Non Comparative ,Investigator Initiated Study , Evaluating the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load Completed NCT00452660 Phase 4 Exjade
14 1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. Completed NCT01250951 Phase 4 Deferasirox
15 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4 deferasirox
16 An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
17 A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasirox) (The MILE Study) Completed NCT00673608 Phase 4 deferasirox
18 An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia Completed NCT01709838 Phase 4 deferasirox
19 Randomized Trial Comparing the Relative Efficacy of Deferiprone to That of Deferoxamine in Removing Excess Cardiac Iron in Thalassemia Major Patients Completed NCT00105495 Phase 4 Ferriprox (deferiprone);Desferal (deferoxamine)
20 Effects of Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients With Iron Overload Recruiting NCT02225886 Phase 4 Ascorbic Acid
21 Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Enrolling by invitation NCT02443545 Phase 4 Deferiprone
22 Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group Terminated NCT01818726 Phase 4 ICL670;Chelation;No chelation
23 A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload. Terminated NCT01326845 Phase 4 Deferasirox
24 A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
25 Effect of Mode of Delivery of Iron and/or Iron and Zinc Supplement on Iron Status Markers and Potential Markers of Iron Toxicity in Children Aged 24-36 Months Unknown status NCT00980421 Phase 3
26 Combined Therapy of Silymarin and Desferrioxamine in Patients With B-thalassemia Major: a Randomized Double-blind Clinical Trial Unknown status NCT00999349 Phase 2, Phase 3 Silymarin (LEGALON);Placebo
27 An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload Completed NCT00171210 Phase 3 Deferasirox
28 A 5-year Open Label, Non-comparative Extension to a Randomized, Open-label, Phase IIa Study to Evaluate Safety, Tolerability and the Effects on Liver Iron Concentration of Repeated Doses of 10 and 20 mg/kg/Day of Deferasirox in Comparison With 40 mg/kg/Day Deferoxamine in Patients With Transfusion-dependent Iron Overload Completed NCT01033747 Phase 2, Phase 3 Deferasirox;Deferasirox
29 Impact of Combination Therapy Between Hydroxy Urea, Omega 3, Nigella Sativa and Honey on Antioxidant-oxidant Status and Reduction of Iron Overload in Pediatric Major Thalassemia Completed NCT04292314 Phase 2, Phase 3 Omega 3;Nigella Sativa Oil;Hydroxyurea;Honey;Deferoxamine
30 A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis Completed NCT00061750 Phase 3 ICL670;deferoxamine
31 Open-label, Multicenter, Single Arm, Phase III Study to Collect Additional Safety and Efficacy Data With Deferasirox Film-coated Tablets in Patients Completing Study CICL670F2201 Completed NCT02720536 Phase 3 Deferasirox
32 A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload Completed NCT00171821 Phase 3 Deferasirox
33 Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies Completed NCT01825512 Phase 3 Deferiprone;Deferasirox
34 A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia Completed NCT00529152 Phase 3 Deferiprone
35 Darbepoetin-alpha and i.v. Iron Administration After Autologous Hematopoietic Stem Cell Transplantation : a Prospective Randomized Trial Completed NCT00557817 Phase 2, Phase 3 Darbepoetin alpha (Aranesp);Iron saccharate (Venofer)
36 Prospective Randomized Study Comparing the Effect of Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only on Glycemia in Patients With Dysmetabolic Liversiderosis Completed NCT01045525 Phase 3
37 A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators Completed NCT00235391 Phase 3 Deferasirox
38 Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Completed NCT01125254 Phase 2, Phase 3 Amlodipine
39 Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major: a Randomized, Controlled Trial Completed NCT01395199 Phase 3 Amlodipine
40 Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease Completed NCT00943748 Phase 2, Phase 3 deferiprone;placebo
41 Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients Completed NCT00350662 Phase 3 Deferiprone (L1);Desferrioxamine
42 A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis Completed NCT00171171 Phase 3 deferasirox
43 Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis. Completed NCT00469560 Phase 3 Deferasirox
44 Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients Recruiting NCT01797055 Phase 2, Phase 3 Human apotransferrin
45 Clinical Importance of Treating Iron Overload in Sickle Cell Disease Terminated NCT00981370 Phase 3 deferasirox
46 Influence of Iron Depletion by Phlebotomy on the Risk of Hepatocellular Carcinoma Occurrence in Patients With Compensated Alcoholic Cirrhosis. Prospective, Multicentre, Randomized Trial Terminated NCT01342705 Phase 3
47 Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS Unknown status NCT03920657 Phase 2 Deferasirox
48 A Multi-Center, Randomized, Open-Label, Parallel Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia Unknown status NCT03381833 Phase 2 LJPC-401;LJPC-401
49 A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload Unknown status NCT01284946 Phase 2 Exjade
50 A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions Completed NCT00600938 Phase 2 Core Study: Deferasirox;Core Study: Deferoxamine;Extension: deferoxamine to deferasirox;Extension: deferasirox to deferoxamine;Deferasirox;Deferoxamine

Search NIH Clinical Center for Hemosiderosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cochrane evidence based reviews: hemosiderosis

Genetic Tests for Hemosiderosis

Anatomical Context for Hemosiderosis

MalaCards organs/tissues related to Hemosiderosis:

Liver, Bone Marrow, Kidney, Bone, Spleen, Heart, Brain

Publications for Hemosiderosis

Articles related to Hemosiderosis:

(show top 50) (show all 11502)
# Title Authors PMID Year
Severe hypochromic microcytic anemia in a patient with congenital atransferrinemia. 54 61
19579082 2009
Hematologic iron analyte values as an indicator of hepatic hemosiderosis in Callitrichidae. 61 54
18366107 2008
Study of the eye and lacrimal glands in experimental iron overload in rats in vivo. 61 54
18402083 2008
Metastatic carcinomatous cirrhosis and hepatic hemosiderosis in a patient heterozygous for the H63D genotype. 61 54
11473464 2001
Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. 61 54
10655270 2000
[A case of hereditary ceruloplasmin deficiency with hemosiderosis]. 61 54
10391079 1999
[Cerebral hemosiderosis related to hereditary ceruloplasmin deficiency. Clinical familial case study]. 61 54
9773037 1998
A novel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis. 54 61
9559983 1998
Hereditary ceruloplasmin deficiency with hemosiderosis. 54 61
8641692 1996
Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. 54 61
7755360 1995
A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. 61 54
7539672 1995
Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy. 61 54
8362602 1993
The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy. 54 61
1585939 1992
Successful treatment of hemosiderosis with regular phlebotomy and recombinant human erythropoietin. Case report and ferrokinetic studies. 61 54
1805491 1991
Usefulness of biochemical screening of diabetic patients for hemochromatosis. 54 61
2351033 1990
Correction of serious iron overload in a chronic hemodialysis patient by recombinant human erythropoietin and removal of red blood cells: confirmation by follow-up liver biopsy. 54 61
2077417 1990
The association between pre-transfusion hemoglobin levels and thalassemia complications. 61
33357151 2021
Analysis of the influencing factors related to liver and cardiac iron overload in MDS patients detected by MRI in the real world. 61
33491605 2021
Dapsone-induced hepatic complications: it's time to think beyond methemoglobinemia. 61
31631707 2021
Clinical and health-related quality of life outcomes of transfusion-dependent thalassaemia patients in Singapore. 61
33607590 2021
Iron deficiency in infancy: current insights. 61
33656466 2021
Sfxn1 is essential for erythrocyte maturation via facilitating hemoglobin production in zebrafish. 61
33524530 2021
Therapeutic potential of iron chelators on osteoporosis and their cellular mechanisms. 61
33601146 2021
Increased zinc and albumin but lowered copper in children with transfusion-dependent thalassemia. 61
33453474 2021
Corrigendum to "PM2.5 induces ferroptosis in human endothelial cells through iron overload and redox imbalance" [Environ. Pollut. 254 (2019) 112937]. 61
32241623 2021
Free-breathing R2∗ mapping of hepatic iron overload in children using 3D multi-echo UTE cones MRI. 61
33432613 2021
Comorbidities and complications in adults with pyruvate kinase deficiency. 61
33370479 2021
Iron overload in aging Bmp6‑/‑ mice induces exocrine pancreatic injury and fibrosis due to acinar cell loss. 61
33649802 2021
Deferoxamine reduces amyloid-beta peptides genesis and alleviates neural apoptosis after traumatic brain injury. 61
33788818 2021
Performance of different Dixon-based methods for MR liver iron assessment in comparison to a biopsy-validated R2* relaxometry method. 61
32965571 2021
Biofilm-specific uptake of a 4-pyridone-based iron chelator by Pseudomonas aeruginosa. 61
33428087 2021
Effect of sevoflurane on iron homeostasis and toxicity in the brain of mice. 61
33539795 2021
Oxidative status in the β-thalassemia syndromes in Sri Lanka; a cross-sectional survey. 61
33677065 2021
Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats. 61
33545199 2021
Spinal NR2B phosphorylation at Tyr1472 regulates IRE(-)DMT1-mediated iron accumulation and spine morphogenesis via kalirin-7 in tibial fracture-associated postoperative pain after orthopedic surgery in female mice. 61
33443215 2021
The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. 61
33454595 2021
Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. 61
32661609 2021
Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients. 61
33388858 2021
Glycosylated ferritin as an improved marker for post-transfusion iron overload. 61
33400141 2021
Red cell transfusion and alloimmunization in sickle cell disease. 61
33792218 2021
The effect of food and nutrients on iron overload: what do we know so far? 61
33712721 2021
How do I…perform therapeutic phlebotomy? 61
33580971 2021
SLC40A1 mediates ferroptosis and cognitive dysfunction in type 1 diabetes. 61
33727075 2021
Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. 61
33774058 2021
Hepatic steatosis and hepatic iron overload modify the association of iron markers with glucose metabolism disorders and metabolic syndrome. 61
33683798 2021
Mitoferrin 2 deficiency prevents mitochondrial iron overload-induced endothelial injury and alleviates atherosclerosis. 61
33711329 2021
Painful Left Bundle Branch Block Syndrome Complicated by Iron-Overload Cardiomyopathy. 61
33746171 2021
Advancement of echocardiography for surveillance of iron overload cardiomyopathy: comparison to cardiac magnetic resonance imaging. 61
33772457 2021
A facile colorimetric method for the quantification of labile iron pool and total iron in cells and tissue specimens. 61
33727584 2021
Targeting mitochondrial iron metabolism suppresses tumor growth and metastasis by inducing mitochondrial dysfunction and mitophagy. 61
33685989 2021

Variations for Hemosiderosis

Expression for Hemosiderosis

Search GEO for disease gene expression data for Hemosiderosis.

Pathways for Hemosiderosis

GO Terms for Hemosiderosis

Cellular components related to Hemosiderosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.02 TF PRTN3 MIF KRT7 HP GPT
2 extracellular region GO:0005576 9.96 TF PRTN3 MIF HP HAMP EPPIN
3 cell surface GO:0009986 9.8 TF SLC11A2 MIF EPPIN EPO
4 blood microparticle GO:0072562 9.62 TF HP CP ALB
5 secretory granule lumen GO:0034774 9.61 TF MIF CAT
6 extracellular space GO:0005615 9.44 TF PRTN3 MIF HP HJV HFE
7 basal part of cell GO:0045178 9.33 TF SLC11A2 HFE
8 HFE-transferrin receptor complex GO:1990712 9.26 TFR2 TF HJV HFE

Biological processes related to Hemosiderosis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.97 TF SLC40A1 SLC11A2 HFE CP
2 cellular oxidant detoxification GO:0098869 9.72 HP CAT ALB
3 transferrin transport GO:0033572 9.67 TFR2 TF HFE
4 iron ion transport GO:0006826 9.62 TFR2 TF SLC11A2 CP
5 response to vitamin A GO:0033189 9.61 HAMP EPO CAT
6 cellular response to iron ion GO:0071281 9.58 TFR2 TF HFE
7 response to hyperoxia GO:0055093 9.57 EPO CAT
8 copper ion transport GO:0006825 9.56 SLC11A2 CP
9 response to iron ion GO:0010039 9.56 TFR2 SLC11A2 HFE HAMP
10 iron ion homeostasis GO:0055072 9.56 TFR2 TF SLC40A1 SLC11A2 HJV HFE
11 acute-phase response GO:0006953 9.55 TFR2 HP HFE HAMP EPO
12 positive regulation of peptide hormone secretion GO:0090277 9.54 TFR2 HFE
13 multicellular organismal iron ion homeostasis GO:0060586 9.54 SLC40A1 SLC11A2 HAMP
14 iron ion transmembrane transport GO:0034755 9.52 SLC40A1 SLC11A2
15 divalent inorganic cation transport GO:0072511 9.51 SLC40A1 SLC11A2
16 response to iron ion starvation GO:1990641 9.48 HFE HAMP
17 regulation of iron ion transport GO:0034756 9.46 TF HFE
18 cellular iron ion homeostasis GO:0006879 9.23 TFR2 TF SLC40A1 SLC11A2 HJV HFE

Molecular functions related to Hemosiderosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 9.43 HAMP CP ALB
2 co-receptor binding GO:0039706 9.37 TFR2 HFE
3 iron ion transmembrane transporter activity GO:0005381 9.32 SLC40A1 SLC11A2
4 ferrous iron transmembrane transporter activity GO:0015093 9.16 SLC40A1 SLC11A2
5 antioxidant activity GO:0016209 9.13 HP CAT ALB
6 transferrin receptor binding GO:1990459 8.8 TF HJV HFE

Sources for Hemosiderosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....